17Sep/20
Blockbuster Deal for ADC: Merck Sharp & Dohme and Seattle Genetics Reach a $4.5 Billion Partnership
On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…